Regen Lab(R) Presents the Latest Clinical Data on the Use of Cellular Matrix(R) Technology in Dermatology, Mixing the Patients Platelet Rich Plasma with Hyaluronic Acid in a One-Step Closed System

Food and Healthcare Press Releases Wednesday September 13, 2017 10:51
LAUSANNE, Switzerland--13 Sep--PRNewswire/InfoQuest

The Journal of American Academy of Dermatology, recently issued "the Efficacy of Autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study" by Hersant B, SidAhmed-Mezi M, Niddam J, La Padula S, Noel W, Ezzedine K, Rodriguez AM, Meningaud JP. ( http://www.jaad.org/article/S0190-9622(17)31769-3/pdf )

(Logo: http://mma.prnewswire.com/media/555148/Regen_Lab_Logo.jpg )
Through published clinical studies, Cellular Matrix technology has also gained acceptance in the field of Musculoskeletal Pain Management, in particular for the treatment of Knee Osteoarthritis.
Released Patents:
  • For the preparation of Platelet Rich Plasma in tubes with a thixotropic separator gel: U.S. patent US8529957, European patent EP2073862B, (...)
  • On the CellularMatrix Technology, for the preparation of Platelet Rich Plasma mixed with Hyaluronic Acid in tubes: U.S. patent US8945537, U.S. patent US9517255, European patent EP2544697B1, Canada, PR. China, Australia, Japan, Russia, Israel, (...)

Regen Lab seeks to enforce its intellectual property and patent rights worldwide. It has already filed numerous patent lawsuits in Europe, PR of China and the United Stated of America ( http://www.prweb.com/releases/2016/11/prweb13849507.htm ).

Regen Lab will be participating in the EADV European Academy of Dermatology 2017 Annual Meeting in Geneva, Switzerland, September 13-17 and the AAD American Academy of Dermatology 2018 Annual Meeting in San Diego, February 16-20.

Additional information about RegenLab, its intellectual property and related actions can be found at http://www.regenlab.com/patents .
Source: Regen Lab SA (Switzerland)

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics